Skip to main content

Advertisement

Table 3 Frequencies of 22 SNPs of 3 genes in metastatic breast cancer patients with and without capecitabine-induced HFS

From: Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer

Gene SNP  Genotype Patients with HFS [cases (%)] Patients without HFS [cases (%)] P value
Total    193 149  
TYMS rs2790 AA 78 (40.4) 48 (32.2)  0.316
  GA 87 (45.1) 74 (49.7)  
  GG 26 (13.5) 24 (16.1)  
  NA 2 (1.0) 3 (2.0)  
rs15872 TT 73 (37.8) 68 (45.6) 0.265
  TC 96 (49.7) 61 (40.9)  
  CC 22 (11.4) 17 (11.4)  
  NA 2 (1.0) 3 (2.0)  
rs699517 TT 73 (37.8) 70 (47.0) 0.195
  TC 97 (50.3) 61 (40.9)  
  CC 20 (10.4) 15 (10.1)  
  NA 3 (1.6) 3 (2.0)  
rs1004474 AA 61 (31.6) 45 (30.2) 0.366
  GA 97 (50.3) 69 (46.3)  
  GG 32 (16.6) 34 (22.8)  
  NA 3 (1.6) 1 (0.7)  
rs2606241 GG 44 (22.8) 34 (22.8) 0.022
  GT 113 (58.5) 69 (46.3)  
  TT 33 (17.1) 44 (29.5)  
  NA 3 (1.6) 2 (1.3)  
rs2853741 TT 38 (19.7) 48 (32.2) 0.019
  TC 113 (58.5) 68 (45.6)  
  CC 39 (20.2) 31 (20.8)  
  NA 3 (1.6) 2 (1.3)  
rs3786362 TT 135 (69.9) 86 (57.7) 0.055
  CT 48 (24.9) 53 (35.6)  
  CC 7 (3.6) 8 (5.4)  
  NA 3 (1.6) 2 (1.3)  
rs9947507 TT 193 (100.0) 149 (100.0) NA
rs9967368 CC 55 (28.5) 52 (34.9) 0.231
  CG 97 (50.3) 61 (40.9)  
  GG 38 (19.7) 33 (22.1)  
  NA 3 (1.6) 3 (2.0)  
MTHFR rs1801131 AA 143 (74.1) 101 (67.8) 0.291
  CA 47 (24.4) 45 (30.2)  
  CC 1 (0.5) 1 (0.7)  
  NA 2 (1.0) 2 (1.3)  
rs1801133 TT 60 (31.1) 52 (34.9) 0.662
  TC 99 (51.3) 69 (46.3)  
  CC 31 (16.1) 25 (16.8)  
  NA 3 (1.6) 3 (2.0)  
rs2274976 GG 163 (84.5) 131 (87.9) 0.558
  GA 26 (13.5) 17 (11.4)  
  AA 1 (0.5) 0 (0.0)  
  NA 3 (1.6) 1 (0.7)  
rs3737964 GG 165 (85.5) 113 (75.8) 0.029
  AG 25 (13.0) 33 (22.1)  
  NA 3 (1.6) 3 (2.0)  
rs3753582 TT 160 (82.9) 131 (87.9) 0.389
  GT 29 (15.0) 15 (10.1)  
  GG 1 (0.5) 1 (0.7)  
  NA 3 (1.6) 2 (1.3)  
rs4846048 AA 165 (85.5) 115 (77.2) 0.030
  AG 25 (13.0) 33 (22.1)  
  NA 3 (1.6) 1 (0.7)  
rs4846049 GG 138 (71.5) 97 (65.1) 0.338
  GT 49 (25.4) 49 (32.9)  
  TT 3 (1.6) 2 (1.3)  
  NA 3 (1.6) 1 (0.7)  
RRM1 rs720106 AA 142 (73.6) 98 (65.8) 0.054
  AG 40 (20.7) 46 (30.9)  
  GG 7 (3.6) 2 (1.3)  
  NA 4 (2.1) 3 (2.0)  
rs725519 AA 142 (73.6) 98 (65.8) 0.532
  AG 40 (20.7) 46 (30.9)  
  GG 7 (3.6) 2 (1.3)  
  NA 4 (2.1) 3 (2.0)  
rs1042858 AA 116 (60.1) 78 (52.3) 0.491
  CA 64 (33.2) 56 (37.6)  
  CC 10 (5.2) 9 (6.0)  
  NA 3 (1.6) 6 (4.0)  
rs1042927 AA 118 (61.1) 81 (54.4) 0.415
  CA 61 (31.6) 57 (38.3)  
  CC 11 (5.6) 9 (6.0)  
  NA 3 (1.6) 2 (1.3)  
rs1980412 CC 61 (31.6) 58 (38.9) 0.359
  TC 102 (52.8) 69 (46.3)  
  TT 26 (13.5) 19 (12.8)  
  NA 4 (2.1) 3 (2.0)  
rs11030918 TT 103 (53.4) 74 (49.7) 0.378
  CT 66 (34.2) 61 (40.9)  
  CC 21 (10.9) 12 (8.1)  
  NA 3 (1.6) 2 (1.3)  
  1. P value < 0.05 was considered statistically significant (in italics)
  2. SNP, single nucleotide polymorphism; HFS, hand-foot syndrome; TYMS, thymidylate synthase; MTHFR, methylene tetrahydrofolate reductase; RRM1, ribonucleotide reductase M1; NA, not applicable